Be the first to like this
Cost benefits and pharmaceutical companies' desire to focus on their core competencies has created an increasing need for outsourcing and spurred the global pharmaceutical contract manufacturing market. Expiring blockbuster drug patents will reduce manufacturing capacity utilization rates and boost outsourcing further.
New analysis from Frost & Sullivan (http://www.lifesciences.frost.com), Global Pharmaceutical Contract Manufacturing Market, finds the market earned revenue of $13.43 billion in 2012 and estimates this to reach $18.49 billion in 2017. This research explores solid dose, liquid and semi-solid dose, and injectable dose formulations.
For more information on this analysis, please email Jennifer Carson, Corporate Communications, at email@example.com, with your full name, company name, job title, telephone number, company e-mail address, company website, city, state and country.